Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Chronic Graft-Versus-Host Disease in Long-Term Survivors of Childhood Leukemia

Blood (2023) 142 (Supplement 1): 3762.

https://doi.org/10.1182/blood-2023-178121

Published: 2023

Journal Articles

Cardiac and Vascular Risks Are the Essential Parameters for Long-Term Surveillance of Lower Risk Childhood Acute Leukemia Survivors

Blood (2022) 140 (Supplement 1): 2187–2189.

https://doi.org/10.1182/blood-2022-157345

Published: 2022

Journal Articles

Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements

Blood (2019) 134 (16): 1351–1355.

https://doi.org/10.1182/blood.2019001244

Published: 2019

Includes: Supplemental data

Journal Articles

Impact of Age and Treatment Group in Childhood High Hyperdiploid Low Risk B-Cell Acute Lymphoblastic Leukemia (ALL): Results of the CLG-EORTC 58951 Study

Blood (2016) 128 (22): 1743.

https://doi.org/10.1182/blood.V128.22.1743.1743

Published: 2016

Journal Articles

Late Effects in Survivors of Infantile Acute Leukemia Are Less Severe Than Expected: A Study of the L.E.a Program

Blood (2016) 128 (22): 3571.

https://doi.org/10.1182/blood.V128.22.3571.3571

Published: 2016

Journal Articles

Metabolic Syndrome in Long-Term Survivors of Childhood Acute Leukemia Treated without Hematopoietic Stem Cell Transplantation: An L.E.Α. Study

Blood (2016) 128 (22): 695.

https://doi.org/10.1182/blood.V128.22.695.695

Published: 2016

Journal Articles

Prophylactic CNS Therapy (with or without Radiation Therapy) in Medium-High Risk Acute Lymphoblastic Leukemia (ALL) Children: Long-Term Outcome Evaluation of the Randomized BFM-Oriented Trial 58832 (period 1983-1989) of the EORTC Children Leukemia Group

Blood (2016) 128 (22): 2775.

https://doi.org/10.1182/blood.V128.22.2775.2775

Published: 2016

Journal Articles

t(12;21)/ ETV6 - RUNX1 Confers a Specific Pattern of In Vivo Sensitivity to Treatments in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Trials 58881 and 58951 of the EORTC Children Leukemia Group

Blood (2015) 126 (23): 793.

https://doi.org/10.1182/blood.V126.23.793.793

Published: 2015

Journal Articles

Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study

Frédéric Millot, Joelle Guilhot, André Baruchel, Arnaud Petit, Yves Bertrand, Françoise Mazingue, Patrick Lutz, Cecile Vérité, Christian Berthou, Claire Galambrun, Nicolas Sirvent, Karima Yakouben, Claudine Schmitt, Virginie Gandemer, Yves Reguerre, Gérard Couillault, Françoise Mechinaud, Jean-Michel Cayuela

Blood (2014) 124 (15): 2408–2410.

https://doi.org/10.1182/blood-2014-05-578567

Published: 2014

Includes: Supplemental data

Journal Articles

Imatinib Has a Negative Impact On Growth In Children With Previously Untreated Chronic Myeloid Leukaemia (CML) In Early Chronic Phase (CP): Results Of The French National Study

Frédéric Millot, Joelle Guilhot, Ph.D., Andre Baruchel, MD, PhD, Arnaud Petit, MD, Thierry Leblanc, MD, Yves Bertrand, Françoise Mazingue, Patrick Lutz, Cécile Vérité, Christian Berthou, Claire Galambrun, Nicolas Sirvent, Karima Yacouben, Pascal Chastagner, Virginie Gandemer, MD, PhD, Yves Reguerre, Gérard Couillaud, Jean-Michel Cayuela

Blood (2013) 122 (21): 4001.

https://doi.org/10.1182/blood.V122.21.4001.4001

Published: 2013

Journal Articles

Molecular Responses At 3 Months Are Associated With a Better Subsequent Molecular response and Outcome In Children and Adolescents With CML In Chronic Phase: Results Of a Retrospective Analysis From The French Glivec Phase 4 Study

Frédéric Millot, Joelle Guilhot, PhD, André Baruchel, MD, Arnaud Petit, MD, Thierry Leblanc, MD, Yves Bertrand, Françoise Mazingue, Patrick Lutz, Cécile Vérité, MD, Christian Berthou, MD, Claire Galambrun, MD, Nicolas Sirvent, Karima Yacouben, Pascal Chastagner, Virginie Gandemer, MD, PhD, Yves Reguerre, MD, Gérard Couillaud, MD, Jean-Michel Cayuela

Blood (2013) 122 (21): 2730.

https://doi.org/10.1182/blood.V122.21.2730.2730

Published: 2013

Journal Articles

Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results

Blood (2013) 121 (13): 2415–2423.

https://doi.org/10.1182/blood-2012-06-437681

Published: 2013

Includes: Supplemental data

Journal Articles

Low CNS Relapse Incidence without Radiotherapy and Improvement of Outcome: Results of Subsequent EORTC-CLG 58881 and 58951 Trials in Pediatric T-Cell Acute Lymphoblastic Leukemia (ALL)

Blood (2012) 120 (21): 133.

https://doi.org/10.1182/blood.V120.21.133.133

Published: 2012

Journal Articles

Prolonged E. Coli Asparaginase Therapy Does Not Improve Significantly the Outcome for Children with Low and Average Risk Acute Lymphoblastic Leukemia (ALL) and Non Hodgkin Lymphoma (NHL): Final Report of the EORTC-CLG Randomized Phase III Trial 58951

Blood (2012) 120 (21): 134.

https://doi.org/10.1182/blood.V120.21.134.134

Published: 2012

Journal Articles

In Childhood B-Lineage Acute Lymphoblastic Leukemia (B-ALL) with Hyperdiploidy >50 Chromosomes, Patients with 58 to 66 Chromosomes Have 99% EFS At 6-Year Follow-up: Results of the EORTC CLG 58951 Trial

Blood (2011) 118 (21): 565.

https://doi.org/10.1182/blood.V118.21.565.565

Published: 2011

Journal Articles

Similar Efficacy and Toxicity Profile for Idarubicine and Mitoxantrone in Induction and Intensification Treatment of Children with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS): Long-Term Results of the EORTC-CLG Randomized Phase III Trial 58921

Barbara De Moerloose, Stefan Suciu, Martine Munzer, Caroline Piette, Karima Yakouben, Genevieve Margueritte, Patrick Lutz, Anne Uyttebroeck, Pierre Rohrlich, MD, PhD, Alina Ferster, Patrick Boutard, Marie-Françoise Dresse, Xavier Rialland, Lucilia Norton, Nicolas Sirvent, Matthias Karrasch, Yves Benoit, MD, Yves Bertrand

Blood (2011) 118 (21): 2615.

https://doi.org/10.1182/blood.V118.21.2615.2615

Published: 2011

Journal Articles

Bone mineral density in adult survivors of childhood acute leukemia: impact of hematopoietic stem cell transplantation and other treatment modalities

Marion Le Meignen, Pascal Auquier, Vincent Barlogis, Nicolas Sirvent, Audrey Contet, Marie-Claude Simeoni, Claire Galambrun, Marilyne Poirée, Pascal Chastagner, Barbara Play, Virginie Villes, Julie Berbis, Hervé Chambost, Pierre Bordigoni, Gérard Michel

Blood (2011) 118 (6): 1481–1489.

https://doi.org/10.1182/blood-2011-01-332866

Published: 2011

Journal Articles

Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia

Claire Oudin, Marie-Claude Simeoni, Nicolas Sirvent, Audrey Contet, Audrey Begu-Le Coroller, Pierre Bordigoni, Catherine Curtillet, Maryline Poirée, Isabelle Thuret, Barbara Play, Mara Carazza Massot, Pascal Chastagner, Hervé Chambost, Pascal Auquier, Gérard Michel

Blood (2011) 117 (17): 4442–4448.

https://doi.org/10.1182/blood-2010-09-304899

Published: 2011

Journal Articles

Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951

Blood (2010) 116 (1): 36–44.

https://doi.org/10.1182/blood-2009-10-247965

Published: 2010

Includes: Supplemental data

Journal Articles

Dexamethasone(DEX)(6mg/sm/d) and Prednisolone(PRED)(60mg/sm/d) in Induction Therapy of Childhood ALL Are Equally Effective: Results of the 2nd Interim Analysis of EORTC Trial 58951

Blood (2008) 112 (11): 8.

https://doi.org/10.1182/blood.V112.11.8.8

Published: 2008

NARROW

Chronic Graft-Versus-Host Disease in Long-Term Survivors of Childhood Leukemia

Cardiac and Vascular Risks Are the Essential Parameters for Long-Term Surveillance of Lower Risk Childhood Acute Leukemia Survivors

Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements

Impact of Age and Treatment Group in Childhood High Hyperdiploid Low Risk B-Cell Acute Lymphoblastic Leukemia (ALL): Results of the CLG-EORTC 58951 Study

Late Effects in Survivors of Infantile Acute Leukemia Are Less Severe Than Expected: A Study of the L.E.a Program

Metabolic Syndrome in Long-Term Survivors of Childhood Acute Leukemia Treated without Hematopoietic Stem Cell Transplantation: An L.E.Α. Study

Prophylactic CNS Therapy (with or without Radiation Therapy) in Medium-High Risk Acute Lymphoblastic Leukemia (ALL) Children: Long-Term Outcome Evaluation of the Randomized BFM-Oriented Trial 58832 (period 1983-1989) of the EORTC Children Leukemia Group

t(12;21)/ ETV6 - RUNX1 Confers a Specific Pattern of In Vivo Sensitivity to Treatments in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Trials 58881 and 58951 of the EORTC Children Leukemia Group

Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study

Imatinib Has a Negative Impact On Growth In Children With Previously Untreated Chronic Myeloid Leukaemia (CML) In Early Chronic Phase (CP): Results Of The French National Study

Molecular Responses At 3 Months Are Associated With a Better Subsequent Molecular response and Outcome In Children and Adolescents With CML In Chronic Phase: Results Of a Retrospective Analysis From The French Glivec Phase 4 Study

Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results

Low CNS Relapse Incidence without Radiotherapy and Improvement of Outcome: Results of Subsequent EORTC-CLG 58881 and 58951 Trials in Pediatric T-Cell Acute Lymphoblastic Leukemia (ALL)

Prolonged E. Coli Asparaginase Therapy Does Not Improve Significantly the Outcome for Children with Low and Average Risk Acute Lymphoblastic Leukemia (ALL) and Non Hodgkin Lymphoma (NHL): Final Report of the EORTC-CLG Randomized Phase III Trial 58951

In Childhood B-Lineage Acute Lymphoblastic Leukemia (B-ALL) with Hyperdiploidy >50 Chromosomes, Patients with 58 to 66 Chromosomes Have 99% EFS At 6-Year Follow-up: Results of the EORTC CLG 58951 Trial

Similar Efficacy and Toxicity Profile for Idarubicine and Mitoxantrone in Induction and Intensification Treatment of Children with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS): Long-Term Results of the EORTC-CLG Randomized Phase III Trial 58921

Bone mineral density in adult survivors of childhood acute leukemia: impact of hematopoietic stem cell transplantation and other treatment modalities

Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia

Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951

Dexamethasone(DEX)(6mg/sm/d) and Prednisolone(PRED)(60mg/sm/d) in Induction Therapy of Childhood ALL Are Equally Effective: Results of the 2nd Interim Analysis of EORTC Trial 58951

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only